Certain combinations of medications used to treat HIV and hepatitis C infection may lead to lower blood levels of these drugs, potentially reducing their efficacy, according to a US Food and Drug Administration (FDA) alert.
Citing evidence from a pharmacokinetic study, the FDA warned that patients taking the hepatitis C–targeted protease inhibitor boceprevir along with any of the ritonavir-boosted HIV-targeting protease inhibitors atazanavir, darunavir, or lopinavir may have lower blood levels of 1 or both drugs. The label of boceprevir will be updated to indicate this potential interaction, and the drug's manufacturer has sent letters to warn physicians.
Kuehn BM. HIV, Hepatitis Drug Interactions. JAMA. 2012;307(12):1243. doi:10.1001/jama.2012.332